We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TALAZOPARIB

News List

Pfizer’s Talzenna cleared for breast cancer pharmatimes
October 19, 2018
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Talazoparib Beneficial in Patients With Advanced Breast Cancer drugs
August 16, 2018
Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and germline BRCA1/2 mutation, according to a study published online Aug. 15 in the New England Journal of Medicine.
Pfizer files PARP inhibitor for breast cancer in US, EU pharmatimes
July 10, 2018
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
TALAZOPARIB SIGNIFICANTLY EXTENDS PROGRESSION-FREE SURVIVAL IN PHASE 3 EMBRACA TRIAL OF PATIENTS WIT pfizer
December 11, 2017
Pfizer Inc. today announced that its Phase 3 EMBRACA trial of patients with reproductive BRCA1 / 2 positive locally advanced and / or metastatic breast cancer has demonstrated excellent progression-free survival